Methods for Treating Bleeding Disorders

Abstract

A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor X1; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor X1-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence on FXI, the method comprising: a) combining a blood or plasma sample comprising activation competent FXI with a composition comprising a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient in activation competent FXI with a composition comprising the sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other, wherein a decrease in the clotting time of the blood sample or an increase in peak thrombin or decrease in peak time of the plasma sample comprising activation competent FXI compared to the clotting time of the blood sample or peak thrombin or peak time of the plasma sample deficient in activation competent FXI is indicative of a NASP which is capable of enhancing blood coagulation in dependence on FXI.

Description

FIELD OF THE INVENTION[0001]The invention relates to methods for treating bleeding disorders, particularly congenital coagulation disorders caused by a blood factor deficiency, chronic or acute bleeding disorders, or acquired coagulation disorders.BACKGROUND OF THE INVENTION[0002]Bleeding disorders, and particularly congenital or acquired deficiencies in coagulation factors, are typically treated by factor replacement. Congenital coagulation disorders include hemophilia, a recessive X-linked disorder involving a deficiency of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B), and von Willebrand's disease, a rare bleeding disorder involving a severe deficiency of von Willebrand factor. Hemophilia C is a milder form of hemophilia caused by a deficiency in factor XI. It is usually asymptomatic, but factor replacement therapy may be required during surgery. Acquired coagulation disorders may arise in individuals without a previous history of bleeding as a result of a di...

AI Technical Summary

Problems solved by technology

Protein therapeutics are produced by recombinant technology or are prepared from plasma and can only be administered intravenously, which is inconvenient.

Although effective, development of inhibitory antibodies which render the therapy ineffective is a common occurrence.

However, such materials would not have been considered suitable for therapy of blood coagulation disorders.

Furthermore, these agents would activate contact activation factors (Factor XII, high molecular weight kininogen or prekallikrein) in vivo, which could be dangerous.

Unregulated bradykinin release might increase vascular permeability, vascular leakage and possibly edema formation.